The aim of this review is to describe the characteristics of patient cohorts commonly used for translational biomarker research in prostate cancer and to outline the most prominent contemporary cohorts which serve as a source of prognostic and predictive biomarkers. A non-systematic review of the literature was performed to identify and summarise well-characterized translational prostate cancer cohorts that provide state-of-the-art characterization of (i) primary and (ii) metastatic and castration-resistant prostate cancer. The main advantages and features of these cohorts are a substantial number of patients, unique patient groups, comprehensive genetic characterisation of tumours using multi-omics/next-generation sequencing approaches, high-quality control standards and fully or partially open data for the research community. This overview includes the contemporary cohorts which serve as a rich source of new targets for prognostic and predictive biomarkers as well as a reference database for validation of known biomarkers, therefore representing the cohorts whose impact extends over the current state of biomarker research into the near future (5-10 years).
Introduction
Prostate cancer (PCA) represents a medicosocial problem with huge morbidity and substantial mortality once development of metastases and transformation into hormone-refractory disease has occurred. 1 So far, the single most relevant biomarker that is commonly used in clinical practice is serum prostate-specific antigen (PSA). Since its introduction in 1970 intense investigations concerning its clinical application and value have been undertaken, and now more than 45 000 PubMed-listed publications (July 2018) mention or deal with this biomarker. 2, 3 Historically, it took some time to realise the full value of this biomarker, to establish cut-off values and subsequent clinical decision trees until, finally, the impact of cohort specifics of underlying studies was recognised. Also, the potential influences of patient age, co-morbidities, race, etc. in the cohorts under scrutiny are now recognised as influences of the PSA detection system. [4] [5] [6] [7] [8] The same holds true for other candidate biomarkers: that cohort characteristics are very important to discern when a new biomarker emerges. In the main clinical situations arising in patients at risk of prostate cancer or after prostate cancer diagnosis (Table 1) , only the first step (whether or not to perform a biopsy) is biomarker-guided to date (based on the analysis of European Association of Urology guidelines, updated March 2018; EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer, accessed at uroweb.org on 01.07.2018), whereas for later stages we still have a strong clinical need to establish new biomarkers. This brief review aims to describe the methodology commonly used for translational biomarker research and to provide information concerning the main translational prostate cancer cohorts having a high impact for modern prostate cancer translation research (Figures 1 and 2 ).
General Considerations: Biomarker Research And Cohort Implications
Biomarkers, defined as a measurable indicator of a disease or more generally a biological condition, are clinically often subdivided into diagnostic, prognostic or predictive markers. 9, 10 Diagnostic biomarkers aid in establishing a diagnosis of a disease. PSA was initially considered a diagnostic biomarker for prostate cancer, but it was soon realised that PSA is more organ-specific than disease-specific. In histology, the loss of basal cells is an important component in the diagnosis of prostate carcinoma, so basal cell markers are considered a diagnostic biomarker. 11 Prognostic biomarkers help to estimate patient outcome. To foresee the natural course of a disease it is important to allow adequate counselling and negotiating treatment options, their effectiveness and associated morbidity. As most patients will opt for curative treatment, finding cohorts of patients who were left untreated is a challenge. Cohorts of watchful waiting patients may be considered as historical, but are therefore invaluable for biomarker researchers. Typical examples are the Scandinavian or the British cohorts of early prostate cancer. [12] [13] [14] [15] Typically, these cohorts are based on needle biopsy material or TUR chips and are thus relatively limited in quantity of tissue for research. Active surveillance (AS) has emerged as a new and attractive curative treatment strategy that aims to postpone active therapy (surgery or irradiation) as long as responsibly possible to save patients the inevitable morbidity that accompanies therapy. Of course, this is only permissible in tumours with a very low risk of progression, according to conventional parameters. Most AS regimens include patients with low PSA levels (<10 ng/ml), Gleason score 6 and limited tumour extent on biopsy (one to two cores). 16, 17 Therefore, biomarkers that broaden these inclusion criteria are highly soughtafter. Currently, it is unclear if tissue-based molecular testing or novel radiological techniques such as multiparametric MRI will be taking the lead in guiding therapy. 18 As AS patients will follow the natural course of the disease, prognostic markers are of importance to correctly assess the risk of disease progression following diagnosis. Conversely, as AS patients are usually rigorously followed-up, these patients allow a particularly detailed monitoring of the progression patterns of early prostate cancer. Hence, AS cohorts are highly sought-after for biomarker research. However, as very little material is usually left after histological diagnosis, the remaining parts are extremely valuable. Also, the typical cohort size of AS patients is fairly limited. 19, 20 Some authors also use the term 'prognostic markers' in the setting of a standard treatment [radical prostatectomy (RP) or radiation therapy (RT)]. As both treatment forms are not specifically targeting a single molecular mechanism or molecule, this view is plausible and welcome to researchers, as it hugely broadens the availability of research material. Therefore, the majority of prognostic marker studies in prostate cancer are based on radical prostatectomy cohorts.
Prostatectomy cohorts are often large, and size may be a quality factor as it can probably compensate for tissue heterogeneity. As most prostatectomy cohorts are currently assembled in tissue microarray format (TMA), which inherently suffers from selection bias (depending on number and size of cores taken), a larger number of cases (>100) is desirable. Ideally, a few hundred cases are represented in a RP cohort. Conversely, perverting the rule of the high number to the extremes may render the cohort 'overpowered', as even biomarkers with very weak prognostic properties and hazard ratios close to 1 may achieve a significant P-value. The only value deduced from these markers is a better comprehension of the biological properties of a biomarker, but the clinical value is blurred, unless a convincing hazard ratio (>1.5) contradicts this. Other quality factors in RP cohorts are uniformity of treatment and inclusion criteria. Cohorts that achieve sufficient numbers only by collecting cases from different centres during a longer period of time Figure 1 . Main principles of organisation and trends in translational prostate cancer studies oriented at prognostic biomarkers. The scope of such studies is finding of biomarkers able to inform about the outcome of the patients which are not being treated actively (watchful waiting, active surveillance) or being treated with such standard modalities as radical prostatectomy or radiation therapy. In case of radical therapy the main source of material for studies is prostatectomy specimens with usually large amounts of tissues available for analysis. However, all other active and non-active strategies rely mainly on the sparse biopsy material or material from transurethral resection. Importantly, even after an almost 40-year history of prognostic biomarker research, no one set of biomarkers made its way into clinical routine with some of them (such as prognostic multigene expression signatures) being under active investigation. Advantages and disadvantages related to translational studies with prognostic biomarkers are outlined below. BCR, Biochemical recurrence; RPE, Radical prostatectomy; PCA, Prostate cancer. may suffer greater heterogeneity, especially as the influence of the surgeons (which is rarely evaluated scientifically as a prognostic factor) is neglected and inclusion criteria and surgical techniques may have changed over time. Unicentric cohorts may have advantages here. In short, prognostic biomarkers can support such decisions as prescribing neoadjuvant or adjuvant therapy in patients before/after radical therapy based on risk stratification regarding their prognosis [e.g. for development of biochemical recurrence (BCR)] or identify patients at high risk of aggressive disease in the post-biopsy setting.
Predictive biomarkers predict the response to a specific therapy, i.e. a therapy that targets a tumourrelevant molecule or mechanism. This is currently not relevant for localised prostate cancer, which is cured by surgery or radiation therapy, but may become relevant for late-stage disease. Predictive biomarkers support the clinical decision concerning the choice and timing of therapy. Predictive biomarkers are often developed or studied parallel to investigations of new medications, mainly in the form of targeted therapy utilising some molecular aberrations in tumour cells or modulating immune responses. Patients with metastatic (mPCA) and castration-resistant PCA (CRPC), where the conventional therapy options are very limited and mortality rates (CRPC) are high, constitute the highest clinical demand for new therapeutics and respective predictive biomarkers. Cohorts aiming to validate predictive markers are usually found in study settings and may be relatively small (e.g. TOPARP trial, n = 50). 
Liquid biopsy
Usually patients with mCSPC/mCRPC Figure 2 . Main principles of organisation in translational prostate cancer studies orientated at predictive biomarkers. The most common group of patients for predictive studies are patients with metastatic prostate cancer which usually require medicament therapy. Specific therapy is therapy with medications targeting certain pathways or molecules. Clinical parameters and end-points used for analysis of therapy efficacy could be radiological, biochemical or clinical progression-free survival, cancer-specific survival and overall survival, as well as response to therapy, extent of response, time-on-therapy and adverse effects. Advantages and disadvantages related to translational studies with prognostic biomarkers are outlined below. AR, Androgen receptor; mCSPC, Metastatic castration-sensitive prostate cancer; mCRPC, Metastatic castration-resistant prostate cancer; Mts, Metastasis; MSI, Microsatellite instability; NGS, Next-generation sequencing.
practice are BCR/serum PSA progression after radical treatment, development of metastases, cancer-specific or overall survival. In AS patients, tumour progression-related end of surveillance and beginning of active therapy is an accepted end-point. Departure from surveillance because of other, i.e. psychic reasons (anxiety), implies a censored case. Another popular parameter for biopsy-related studies that does not necessitate a longer observation time is adverse pathology of the subsequent RP specimen (i.e. pT3, Gleason scores >7). This is, of course, only a surrogate parameter, as even though adverse pathology generally indicates a higher likelihood of poorer outcome, individual courses may still be highly variable. Also, using this surrogate endpoint may imply a selection bias, as only biopsy patients eligible for radical prostatectomy are analysed.
As prostate cancer often pursues a protracted course, early end-points that do not necessitate long observation times are welcome. Hence, biochemical recurrence (BCR)/ disease-free survival (DFS) is the first and most commonly used end-point in many RP cohort studies. Even with median follow-up times of only 4-5 years, BCR as an endpoint may allow meaningful analyses of prognostic factors and longer times are even better. However, not every PSA relapse will translate into earlier death from prostate cancer, which represents the hardest end-point. Hence, BCR is considered a surrogate marker and opinions upon its value vary. 22, 23 Most authors define a BCR as a rising PSA >0.2 ng/ml, but it is also important to note that definitions of BCR may also vary. 24 An increasingly popular intermediate surrogate end-point for prostate cancer death is metastasis-free survival (MFS). A recent meta-analysis of 28 prostate cancer trials encompassing 28 900 patients analysed DFS and MFS times and found that MFS correlated more closely with cancer-related death. The authors concluded that: 'MFS is a strong surrogate for OS in clinically localised prostate cancer in a patient population with an approximate 15% chance of dying of prostate cancer over 10 years despite potentially curative local therapy'. 25 This was recently endorsed by Jackson et al., who found that distant metastasis (DM) at 5 years had the strongest association with overall survival times. 26 As mentioned previously, the ideal end-point is disease-specific survival, which is also the preferred end-point in studies of late-stage or castration-resistant (CRPC) prostate cancer.
Review Methodology
In this review we performed a screening of scientific literature with the aim of identifying well-characterised translational prostate cancer cohorts for prognostic and predictive studies which serve as the main sources of scientific findings able to change clinical decision-making in patients with PCA. The number of prostate cancer patient cohorts in the literature is overwhelming, with patient numbers varying from 10 to more than 13 000 patients. Moreover, most of these cohorts address single biomarkers with a singleomics approach or used for single studies without solid history of further publications. Therefore, only certain types of cohort fell under the scope of this review, namely (i) translational (often international or multi-institutional) cohorts of high quality utilising a multi-omics approach, modern molecular characterisation techniques (such as next-generation sequencing, NGS) and rigorous quality control standards reducing typical biases of cohort studies; and (ii) large well-characterised and currently active translational cohorts with a history of numerous publications.
Our motivation for using these criteria was dominated by the attempt to create a list of cohorts who are not only interesting from a historical perspective, but also operate at the present time and will still have significance in the near future, due to their comprehensive and visionary nature. In simple words, these are the cohorts that could be used as reference for planning and validation of studies, testing scientific hypotheses and serving as a hub of information concerning prognostic and predictive biomarkers, often available for data mining and still carrying large investigative potential.
D A T A S Y N T H E S I S
All prostate cancer translational cohorts could be classified into several groups. Two main groups are cohorts of patients with (i) primary prostate cancer, treated with expectant management, RPE or RT and (ii) with mPCA or CRPC. Between these two groups, certain subclassification is possible based on the approaches used for investigations. The top of these groups is represented by several major efforts to characterise PCA on a molecular genetic level using modern technologies (Tables 2 and 3) .
One of the well-known translation prostate cancer cohorts is The Cancer Genome Atlas (TCGA) cohort, with 499 patients with clinically localised PCA treated with RPE. The TCGA investigators have issued only two publications (one of them together with the CPC-GENE group), with global analysis of primary prostate cancer molecular biology 27, 28 based on exome, RNA and microRNA sequencing alternative RNA splicing, genome-wide DNA methylation analysis and copy-number analysis (low-pass DNAseq and SNP arrays), as well as proteomics. All these data are open-source and represent a huge source for further investigations, validation of smaller studies and testing of hypotheses. As all patients in the TCGA cohort were treated with radical prostatectomy, being the current standard treatment, diagnostic and prognostic biomarkers (biochemical recurrence as end-point), but not predictive biomarkers, could be a target while using this cohort. Similar prominent genetic characterisation efforts are also known for mPCA and CRPC, with a remarkable comparative compilation by Armenia et al. in 2018 including 680 primary cases and 333 metastatic cases, shedding light on many issues related to genetics and the evolution of prostate cancer, many of which were already highlighted by some major efforts outlined in Table 3 . 29 These cohorts have a strong emphasis on predictive biomarkers. Average overall survival in patients with chemotherapy-naive mCRPC in modern cohorts is approaching 25-30 months. 30 This critical group of patients is in constant need of new medications. Although many clinical trials are ongoing, the main hope is related to targeted attempts, i.e. trying to exploit known recurrent or seldom genetic alterations in CRPC tumours. Therefore, the studies listed in Table 3 are the main source of ideas for new targeted medications, on one hand, and for predictive biomarkers, on the other hand. So far, only a small percentage of the information from these comprehensive studies is currently under further development. The main efforts nowadays are concentrated on the most recurrent genetic alterations (with a frequency of 5-10% and more). For example, one recent study has shown that SPOP mutations and/or CHD1-deletions present in more than 10% of patients with primary and lethal PCA confer a higher response rate and longer responses to abiraterone. 31 In clinical terms, this means that SPOP/CHD1-status is a predictive biomarker able to extend life through optimal timing and selection of medicaments in every tenth patient with metastatic PCA. A huge number of other targets and potential predictive biomarkers with a frequency of genetic alteration of less than 5% is available from the above-mentioned cohorts (Table 3) for further studies of personalised medicine approaches.
The advantage of the mPCA/CRPC cohorts is availability of robust end-points (progression-free survival and overall survival) which are reachable in the foreseeable future and making such studies time-efficient compared to cohorts of primary patients, where 10-15 years of follow-up are often needed to reach these important end-points. Therefore, the output of the above-mentioned comprehensive studies, both in primary PCA and mPCA/ CRPC, provides a comprehensive understanding of PCA molecular biology, natural and therapy-driven tumour evolution and serves as an important source of putative diagnostic, prognostic and predictive biomarkers for further studies. The raw data from these studies are often available for subanalyses and data mining (see Tables 2 and 3 ).
There are several other notable cohorts consisting of patients with primary prostate cancer ( Table 2) known for their large patient groups (UKE, Transatlantic Prostate Group and Charit e cohorts), unique patient group (Transatlantic Prostate Group cohort of patients with watchful waiting/conservatively treated patients) and an ongoing history of publications of prognostic biomarkers. One of the disadvantages of these cohorts which should be mentioned here is the material used for analysis. All these cohorts use tissue from patients arranged in the form of TMA as the main source of material that restricts the use of multi-omics and NGS approaches, leaving in-situ hybridisation methods and immunohistochemistry as the main tools. Nevertheless, the mentioned cohorts provide valuable input through these clinical-level methods, often in the form of validation/investigation of already-known biomarker targets.
One type of translational PCA patient cohorts was intentionally left out of our attention; namely, patient cohorts used for the development of prognostic mRNA expression signatures in patients with primary PCA. Some of them have undergone a history of multiple validation attempts and have provided a ground for commercial products. As these cohorts were orientated mainly at particular signatures or products and were not intended to use as translational cohorts for further biomarker research, they do not adhere to our selection criteria. However, an excellent overview and recent validation of these cohorts in a large group of patients with clinically low-risk prostate cancer (n = 408) was conducted by Cooperberg et al.
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Conclusions
This review provides an overview of the translational prostate cancer cohorts consisting of patients with primary and metastatic or castration-resistant PCA. It includes primarily the contemporary cohorts, which serve as a rich source of new targets for prognostic and predictive biomarkers as a well as a reference database for validation of known biomarkers, i.e. the cohorts whose impact extends over the current state of
